Drugs / Membrane-bound Interleukin-21-Expanded Haploidentical Natural Killer Cells
Membrane-bound Interleukin-21-Expanded Haploidentical Natural Killer Cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01787474 | May 2014 → Jun 2021 | acute myeloid leukemia | M.D. Anderson Cancer Center | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Membrane-bound Interleukin-21-Expanded Haploidentical Natural Killer Cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01787474 ↗ |
| Action | Deplete | “causing it to destroy them” NCT01787474 ↗ |
| Modality | Cell therapy | “membrane-bound interleukin-21-expanded haploidentical natural killer cells” NCT01787474 ↗ |
| Route | Intravenous | “Given IV” NCT01787474 ↗ |